Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study.
BRAF inhibitor
MEK inhibitor
anti-PD1
melanoma
targeted therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Jun 2020
23 Jun 2020
Historique:
received:
29
05
2020
revised:
19
06
2020
accepted:
19
06
2020
entrez:
27
6
2020
pubmed:
27
6
2020
medline:
27
6
2020
Statut:
epublish
Résumé
Despite significant progress in melanoma survival, therapeutic options are still needed in case of progression under immune checkpoint inhibitors (ICI), and resistance to targeted therapies (TT) in BRAF-mutated melanomas. This study aimed to assess the safety of combined ICI and TT as a rescue line in real-life clinical practice. We conducted a study within the prospective French multicentric MelBase cohort, including patients treated with a combination of anti-PD1 (pembrolizumab/nivolumab) and BRAF inhibitor (BRAFi: dabrafenib/vemurafenib) and/or MEK inhibitors (MEKi: trametinib/cobimetinib) for BRAF mutated or wild-type advanced melanoma. Fifty-nine patients were included: 30% received the triple combination, 34% an anti-PD1 and BRAFi, and 36% an anti-PD1 and MEKi. Grade 3-4 adverse events occurred in 12% of patients. Permanent discontinuation or dose reduction of one of the treatments for toxicity was reported in 14% and 7% of patients, respectively. In the BRAF wild-type subgroup, treatment with MEKi and anti-PD1 induced a tumor control rate of 83% and median progression-free survival of 7.1 months. The combination of anti-PD1 and BRAFi and/or MEKi was a safe rescue line for advanced melanoma patients previously treated with ICI/TT. The benefit of these combinations, specifically anti-PD1 and MEKi in BRAF wild-type melanoma patients, needs to be prospectively studied.
Identifiants
pubmed: 32585901
pii: cancers12061666
doi: 10.3390/cancers12061666
pmc: PMC7352575
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Med. 2019 Jun;25(6):941-946
pubmed: 31171878
Cancer Res. 2012 Aug 15;72(16):3928-37
pubmed: 22693252
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Clin Cancer Res. 2012 Mar 1;18(5):1386-94
pubmed: 22156613
Lancet. 2015 Aug 1;386(9992):444-51
pubmed: 26037941
J Clin Oncol. 2014 Jul 20;32(21):2248-54
pubmed: 24958825
Lancet Oncol. 2016 Sep;17(9):1248-60
pubmed: 27480103
Cancer Res. 2010 Jul 1;70(13):5213-9
pubmed: 20551059
Lancet Oncol. 2017 Apr;18(4):435-445
pubmed: 28284557
Clin Cancer Res. 2013 Jan 15;19(2):393-403
pubmed: 23204132
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Lancet Oncol. 2018 May;19(5):603-615
pubmed: 29573941
Ann Oncol. 2017 Jul 1;28(7):1631-1639
pubmed: 28475671
Eur J Cancer. 2018 Jul;98:10-16
pubmed: 29843107
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Nat Med. 2019 Jun;25(6):929-935
pubmed: 31171876
Clin Cancer Res. 2013 Mar 1;19(5):1225-31
pubmed: 23307859
Pigment Cell Melanoma Res. 2013 Jul;26(4):499-508
pubmed: 23557327
N Engl J Med. 2013 Apr 4;368(14):1365-6
pubmed: 23550685
Nat Med. 2019 Jun;25(6):936-940
pubmed: 31171879
Clin Cancer Res. 2013 Feb 1;19(3):598-609
pubmed: 23095323
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Ther Adv Med Oncol. 2019 Feb 19;11:1758835919830826
pubmed: 30815041
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494